Companies /Healthcare
Alnylam Pharmaceuticals Inc
NASDAQ: ALNY Biotechnology
$159.89
▲ $1.89 (+1.20%) today
Markets closed · 6:19pm ET

Alnylam Pharmaceuticals (ALNY) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
71%
EPS beat rate
+122.11%
Avg. EPS surprise
Consecutive EPS beats
ALNY vs Market · 30-day return after each reportALNYS&P 500
−7%0%+7%+14%+0.5%+2.7%Q4 23+14.0%+1.3%Q2 25+3.4%+0.3%Q3 25+3.9%−1.5%Q4 25−7.6%+5.7%Q1 26+17.1%+3.4%Q2 26
−7%0%+7%+14%Q4 23Q3 25Q1 26
ALNY EPS Trend · estimate vs actualEstimateActual
$0$5$10$15$-1.32$-0.77Q4 23$0.15$0.32Q2 25$1.75$2.90Q3 25$1.50$1.25Q4 25$1.47$1.99Q1 26$2.15$1.84Q2 26$2.25$16.26Q3 26
$0$5$10$15Q4 23Q3 25Q1 26Q3 26
ALNY Revenue Trend · estimate vs actualEstimateActual
$0$500.0M$1.0B$1.5B$442.9M$439.7MQ4 23$662.5M$773.7MQ2 25$974.1M$1.2BQ3 25$1.2B$1.1BQ4 25$1.1B$1.2BQ1 26$1.3B$1.3BQ2 26$1.4B$1.5BQ3 26
$0$500.0M$1.0B$1.5BQ4 23Q3 25Q1 26Q3 26

How Often Does Alnylam Pharmaceuticals Beat Earnings Estimates?

Alnylam Pharmaceuticals beat EPS estimates in 5 of its last 7 reported quarters.

ALNY quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Includes a benefit from income taxes of $1.9 billion ($1,871.5 million on the income statement), primarily related to the release of valuation allowances on certain U.S. federal and state deferred tax assets; this benefit is not excluded from non-GAAP net income. $16.26 est. $2.25 +622.99% $1.5B est. $1.4B +2.03%
Q2 2026 $1.84 est. $2.15 −14.47% $1.3B est. $1.3B −2.28%
Q1 2026 $1.99 est. $1.47 +35.30% $1.2B est. $1.1B +4.53%
Q4 2025 $1.25 est. $1.50 −16.49% $1.1B est. $1.2B −5.21%
Q3 2025 $2.90 est. $1.75 +66.12% $1.2B est. $974.1M +28.22%
Q2 2025 $0.32 est. $0.15 +119.63% $773.7M est. $662.5M +16.79%
Q4 2023 $-0.77 est. $-1.32 +41.67% $439.7M est. $442.9M −0.72%

Figures from SEC filings and company reports. Not investment advice.